Mallinckrodt Pharmaceuticals (MNK) Reports Human Abuse Liability (HAL) Data for MNK-795, an Extended-Release Oxycodone/Acetaminophen Combination  
9/4/2013 11:18:42 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LAS VEGAS--(BUSINESS WIRE)--Mallinckrodt (NYSE: MNK) today reported data from a Human Abuse Liability (HAL) study comparing certain abuse-related characteristics of MNK-795 with those of Percocet (an immediate-release oxycodone/acetaminophen formulation). In the HAL study, intact and crushed MNK-795 had statistically significant (p <0.001) lower measures of drug liking, drug high, and good drug effects than comparable doses of Percocet when measured at the peak drug effect (Emax). The data are being presented at PAINWeek, a national conference on pain for frontline practitioners, taking place in Las Vegas September 4-7, 2013.

Help employers find you! Check out all the jobs and post your resume.